Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases.

ABSTRACT:

Background

Very little is known about the impact of the wash-out period on the pharmacokinetics of a second-line biologic.

Objective

The objective of this article is to explore the impact of two different wash-out periods on the pharmacokinetics of vedolizumab and infliximab.

Methods

Patients switching from infliximab to vedolizumab were retrospectively identified. The population was divided into two groups according to wash-out period: <6 weeks or >6 weeks. Vedolizumab and infliximab trough levels (TLs) were determined and correlated with clinical and biological outcomes.

Results

A total of 71 inflammatory bowel disease patients were included. At week 6, in patients previously treated with infliximab, median vedolizumab TLs were 21.9 µg/ml and 24.9 µg/ml for t

SUBMITTER: Liefferinckx C 

PROVIDER: S-EPMC6620879 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature